Elizabeth Honorato de Farias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elizabeth Honorato de Farias has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anderson Matheus Pereira da Silva
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, Brazil
3 shared publications - Mariana Letícia de Bastos Maximiano
Federal Fluminense University
2 shared publications - Ahmet Günkan
Department of Radiology and Imaging Sciences, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, USA
1 shared publication - Aishwarya Koppanatham
Andhra Medical College, King George Hospital, Visakhapatnam, India
1 shared publication - Altair Pereira de Melo Neto
Federal University of Roraima , Boa Vista , Roraima, Brazil
1 shared publication - Ana Gabriela Alves Pereira
Universidade do Estado de São Paulo São PauloSP Brazil Universidade do Estado de São Paulo, São Paulo, SP, Brazil
1 shared publication
Latest Publications
- 11 April 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Reperfusion therapy in pregnant and postpartum women after ischemic stroke: a systematic review and single-arm meta-analysis
Ischemic stroke during pregnancy and postpartum represents a rare but severe clinical event. Although reperfusion therapies like intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are standard in the general population, their use in pregnant and postpartum patients remains controversial due to limited data. Therefore, this study aims to evaluate the safety and efficacy of reperfusion therapy in pregnant and postpartum women with acute ischemic stroke. Systematic review and single-arm meta-analysis of studies reporting outcomes in pregnant or postpartum women undergoing IVT or MT. Outcomes included maternal and fetal events, intracerebral hemorrhage (ICH), symptomatic ICH (sICH), functional recovery (mRS 0-2), and mortality. Six studies comprising 275 patients were included. The pooled proportion of good maternal outcomes at discharge was 50% (95% CI: 44%-56%), and 85% (95% CI: 53%-100%) achieved functional recovery at 3 months. In-hospital mortality was 0% (95% CI: 0%-1%). Hemorrhagic complications included 10% ICH (95% CI: 1%-20%) and 3% sICH (95% CI: 0%-9%). Good fetal outcomes were observed in 78% (95% CI: 50%-100%) of cases. Although limited, the results suggest that reperfusion therapy in pregnancy-related ischemic stroke is safe and potentially effective, with favorable maternal and fetal outcomes and low mortality rates. These findings support the use of reperfusion therapies associated with individualized decision-making-in line with European Stroke Organisation guidelines -, emphasizing that pregnancy and post-partum period should not be a contraindication to IVT or MT.
- 11 April 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Reperfusion therapy in pregnant and postpartum women after ischemic stroke: a systematic review and single-arm meta-analysis
Ischemic stroke during pregnancy and postpartum represents a rare but severe clinical event. Although reperfusion therapies like intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are standard in the general population, their use in pregnant and postpartum patients remains controversial due to limited data. Therefore, this study aims to evaluate the safety and efficacy of reperfusion therapy in pregnant and postpartum women with acute ischemic stroke. Systematic review and single-arm meta-analysis of studies reporting outcomes in pregnant or postpartum women undergoing IVT or MT. Outcomes included maternal and fetal events, intracerebral hemorrhage (ICH), symptomatic ICH (sICH), functional recovery (mRS 0-2), and mortality. Six studies comprising 275 patients were included. The pooled proportion of good maternal outcomes at discharge was 50% (95% CI: 44%-56%), and 85% (95% CI: 53%-100%) achieved functional recovery at 3 months. In-hospital mortality was 0% (95% CI: 0%-1%). Hemorrhagic complications included 10% ICH (95% CI: 1%-20%) and 3% sICH (95% CI: 0%-9%). Good fetal outcomes were observed in 78% (95% CI: 50%-100%) of cases. Although limited, the results suggest that reperfusion therapy in pregnancy-related ischemic stroke is safe and potentially effective, with favorable maternal and fetal outcomes and low mortality rates. These findings support the use of reperfusion therapies associated with individualized decision-making-in line with European Stroke Organisation guidelines -, emphasizing that pregnancy and post-partum period should not be a contraindication to IVT or MT.
- Open Access
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (08) , 001-008
Corticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis
Although it is known that the most commonly used therapies for West syndrome (WS) are intramuscular adrenocorticotropic hormone (ACTH) and oral prednisolone, there is still controversy in the literature regarding the equivalence of their effects.We aimed to present an updated review comparing the therapeutic and adverse effects of ACTH therapy versus corticosteroids in children with West syndrome (WS).The PubMed, EMBASE, and Cochrane Central databases were searched. The outcomes of interest selected were spasm cessation on day 14 of therapy, cessation of hypsarrhythmia and adverse effects such as weight gain, infection, irritability, and hypertension. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed. We compared the results using the risk ratio (RR) and odds ratio (OR). for the binary outcomes, with 95% confidence intervals (CI) and a random-effects model. Statistical analysis was performed using RevMan 5.1.7.Compared with corticoids, ACTH was associated with a significant increase in weight (RR: 1.41; 95% CI: 1.01–1.97; p = 0.04). There was no significant difference in cessation of spasms on day 14 (OR: 0.91; 95% CI: 0.47–1.47; p = 0.79), hypsarrhythmia (OR: 0.97; 95% CI: 0.22–4.34), irritability (RR: 0.78; 95% CI: 0.30–1.99), hypertension (RR: 0.64; 95% CI: 0.35–1.15; p = 0.14), and infection (RR: 0.69; 95% CI: 0.19–2.50; p = 0.57).This study provides robust evidence regarding the safety and efficacy of ACTH or corticoids in children with WS. However, the significant heterogeneity between studies restricts the analysis, emphasizing the need for additional research to assess the best WS treatment option.
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (08) , 001-008
Open AccessCorticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis
Although it is known that the most commonly used therapies for West syndrome (WS) are intramuscular adrenocorticotropic hormone (ACTH) and oral prednisolone, there is still controversy in the literature regarding the equivalence of their effects.We aimed to present an updated review comparing the therapeutic and adverse effects of ACTH therapy versus corticosteroids in children with West syndrome (WS).The PubMed, EMBASE, and Cochrane Central databases were searched. The outcomes of interest selected were spasm cessation on day 14 of therapy, cessation of hypsarrhythmia and adverse effects such as weight gain, infection, irritability, and hypertension. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed. We compared the results using the risk ratio (RR) and odds ratio (OR). for the binary outcomes, with 95% confidence intervals (CI) and a random-effects model. Statistical analysis was performed using RevMan 5.1.7.Compared with corticoids, ACTH was associated with a significant increase in weight (RR: 1.41; 95% CI: 1.01–1.97; p = 0.04). There was no significant difference in cessation of spasms on day 14 (OR: 0.91; 95% CI: 0.47–1.47; p = 0.79), hypsarrhythmia (OR: 0.97; 95% CI: 0.22–4.34), irritability (RR: 0.78; 95% CI: 0.30–1.99), hypertension (RR: 0.64; 95% CI: 0.35–1.15; p = 0.14), and infection (RR: 0.69; 95% CI: 0.19–2.50; p = 0.57).This study provides robust evidence regarding the safety and efficacy of ACTH or corticoids in children with WS. However, the significant heterogeneity between studies restricts the analysis, emphasizing the need for additional research to assess the best WS treatment option.
- 19 June 2025
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 44 (3) , 246-256
Buprenorphine-naloxone vs methadone for opioid use disorder: a systematic review and meta-analysis of randomized clinical trials
Background: This meta-analysis evaluated the efficacy and safety of buprenorphine-naloxone compared to methadone in the treatment of Opioid Use Disorder (OUD), with a focus on treatment retention, attrition rates, and serious adverse events. OUD remains a major public health concern, necessitating effective pharmacological interventions to improve adherence and minimize adverse outcomes.Methods: A systematic search of PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus identified randomized controlled trials comparing both treatments. The study adhered to PRISMA guidelines, and data were analyzed using a random-effects model with Odds Ratios (OR) and 95% Confidence Intervals (CI). Heterogeneity was assessed using the I2 statistic.Results: Seven randomized controlled trials involving 3,622 patients were included. Methadone doses ranged from 5 to 397 mg/day and buprenorphine-naloxone from 2 to 32 mg/day. Methadone showed significantly higher treatment retention at six months compared to buprenorphine-naloxone (OR 0.43; 95% CI 0.27-0.67; I2 = 62.2%). Attrition was higher in the buprenorphine-naloxone group (OR 2.47; 95% CI 1.42-4.30; I2 = 68.4%). In contrast, serious adverse events occurred less frequently with buprenorphine-naloxone (OR 0.72; 95% CI 0.48-1.09; I2 = 0.0%).Conclusion: In conclusion, methadone is associated with superior retention, while buprenorphine-naloxone presents a more favorable safety profile. These findings highlight the need for individualized treatment decisions based on clinical context and patient-specific risks. Future large-scale, high-quality studies are recommended to guide optimal pharmacological strategies for managing OUD. PROSPERO protocol number: CRD 42025634919.
- 19 June 2025
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 44 (3) , 246-256
Buprenorphine-naloxone vs methadone for opioid use disorder: a systematic review and meta-analysis of randomized clinical trials
Background: This meta-analysis evaluated the efficacy and safety of buprenorphine-naloxone compared to methadone in the treatment of Opioid Use Disorder (OUD), with a focus on treatment retention, attrition rates, and serious adverse events. OUD remains a major public health concern, necessitating effective pharmacological interventions to improve adherence and minimize adverse outcomes.Methods: A systematic search of PubMed, Embase, Cochrane CENTRAL, Web of Science, and Scopus identified randomized controlled trials comparing both treatments. The study adhered to PRISMA guidelines, and data were analyzed using a random-effects model with Odds Ratios (OR) and 95% Confidence Intervals (CI). Heterogeneity was assessed using the I2 statistic.Results: Seven randomized controlled trials involving 3,622 patients were included. Methadone doses ranged from 5 to 397 mg/day and buprenorphine-naloxone from 2 to 32 mg/day. Methadone showed significantly higher treatment retention at six months compared to buprenorphine-naloxone (OR 0.43; 95% CI 0.27-0.67; I2 = 62.2%). Attrition was higher in the buprenorphine-naloxone group (OR 2.47; 95% CI 1.42-4.30; I2 = 68.4%). In contrast, serious adverse events occurred less frequently with buprenorphine-naloxone (OR 0.72; 95% CI 0.48-1.09; I2 = 0.0%).Conclusion: In conclusion, methadone is associated with superior retention, while buprenorphine-naloxone presents a more favorable safety profile. These findings highlight the need for individualized treatment decisions based on clinical context and patient-specific risks. Future large-scale, high-quality studies are recommended to guide optimal pharmacological strategies for managing OUD. PROSPERO protocol number: CRD 42025634919.